Vai al contenuto principale
xMedica

NCT07817251ClinicalTrials.gov

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…

Fase 3210 partecipanti ricercati40 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 210 participants (target), run at 40 sites.

How this score is built
  • Enrolment22/40

    210 participants (target)

  • Site count19/25

    40 sites

  • Country count0/15

    Single country

  • Planned duration4/10

    Planned over about 10 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 339 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Patologie

  • Diabetes Mellitus, Type 2

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento210 partecipanti ricercati

Sponsor e collaboratori

  • Novo Nordisk A/S Sponsor

Bracci e interventi

  • CagriSema dose 1EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.

  • CagriSema dose 2EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.

  • CagriSema dose 3EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.

Interventi

  • Farmaco CagriSema

    CagriSema will be administered s.c. once weekly.

Esiti misurati

  1. Esito primario

    Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Orizzonte temporale From baseline (Week 0) to end of treatment (Week 16)

  2. Esito secondario

    Number of TEAEs

    Measured as count of events.

    Orizzonte temporale From baseline (Week 0) to end of study (Week 22)

  3. Esito secondario

    Number of TEAEs

    Measured as count of events.

    Orizzonte temporale From baseline (Week 0) to Week 8

  4. Esito secondario

    Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)

    Measured as count of episodes.

    Orizzonte temporale From baseline (Week 0) to end of study (Week 22)

  5. Esito secondario

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Orizzonte temporale From baseline (Week 0) to end of study (Week 22)

  6. Esito secondario

    Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Measured as count of episodes.

    Orizzonte temporale From baseline (Week 0) to Week 8

  7. Esito secondario

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Orizzonte temporale From baseline (Week 0) to Week 8

  8. Esito secondario

    Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)

    Measured as count of participants.

    Orizzonte temporale From baseline (Week 0) to end of treatment (Week 16)

Date

Date
Data di inizio16 settembre 2026 (effettiva)
Conclusione primaria9 giugno 2027 (stimata)
Conclusione21 luglio 2027 (stimata)
Prima pubblicazione14 settembre 2026 (effettiva)
Ultimo aggiornamento30 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

37 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Albuquerque Clinical Trials Inc.AlbuquerqueNew MexicoIn reclutamento
Amarillo Med Spec LLPAmarilloTexasIn reclutamento
Texas Diabetes & EndocrinologyAustinTexasIn reclutamento
Northern Pines Hlth Ctr, PCBuckleyMichiganIn reclutamento
North Texas Endocrine CenterDallasTexasIn reclutamento
Northeast Research InstituteFleming IslandFloridaIn reclutamento
Diabetes and Thyroid Center of Fort WorthFort WorthTexasIn reclutamento
Ark Clinical ResearchFountain ValleyCaliforniaIn reclutamento
Gilbert Center For Family MedicineGilbertArizonaIn reclutamento
Thrive Clinical Research GroupGlendoraCaliforniaIn reclutamento
PharmQuest Life Sciences LLCGreensboroNorth CarolinaIn reclutamento
AGA Clinical TrialHialeahFloridaIn reclutamento
East West Med Res InstHonoluluHawaiiIn reclutamento
JCCT- Juno NW HoustonHoustonTexasIn reclutamento
Sante Clinical ResearchKerrvilleTexasIn reclutamento
Scripps Whittier Diabetes InstLa JollaCaliforniaIn reclutamento
Palm Research Center Inc-VegasLas VegasNevadaIn reclutamento
DCOL Ctr for Clin ResLongviewTexasIn reclutamento
Downtown LA Res Ctr. Inc.Los AngelesCaliforniaIn reclutamento
Advanced Medical ResearchMaumeeOhioNon ancora in reclutamento
Adult Medicine of Lake County, IncMt. DoraFloridaIn reclutamento
Clinical Research AssociatesNashvilleTennesseeIn reclutamento
Tidewater Physicians Multispecialty GroupNewport NewsVirginiaIn reclutamento
Alliance for Multispecialty ResearchNewtonKansasIn reclutamento
North Hills Medical Research IncNorth Richland HillsTexasIn reclutamento
Valley Clinical Trials, Inc.NorthridgeCaliforniaIn reclutamento
Optimal Research SitesOrange CityFloridaIn reclutamento
Dream Team Clinical ResearchPomonaCaliforniaIn reclutamento
Clinical Trials Research_SacramentoSacramentoCaliforniaIn reclutamento
J.Lewis Research IncSalt Lake CityUtahIn reclutamento
NE Clin Res of San AntonioSan AntonioTexasNon ancora in reclutamento
Linda Vista Health Care CtrSan DiegoCaliforniaIn reclutamento
Diabetes & Endo Treatment SpecSandy CityUtahNon ancora in reclutamento
Endeavor HealthSkokieIllinoisIn reclutamento
Chrysalis Clinical ResearchSt. GeorgeUtahIn reclutamento
Cotton O'Neil Diabetes & EndocrinologyTopekaKansasIn reclutamento
Chase Medical Research LLCWaterburyConnecticutIn reclutamento
Iowa Diabetes & Endo Res CtrWest Des MoinesIowaIn reclutamento
Metabolic Research Institute IncWest Palm BeachFloridaIn reclutamento
Accellacare WilmingtonWilmingtonNorth CarolinaIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 30 settembre 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 30 settembre 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING